Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11–2012/13

Andrea Streng1*, Christiane Prifert2, Benedikt Weissbrich2, Johannes G. Liese1, for the Bavarian PICU Study Group on Influenza and Other Viral ARI

Abstract

Background: Previous influenza surveillance at paediatric intensive care units (PICUs) in Germany indicated increased incidence of PICU admissions for the pandemic influenza subtype A(H1N1)pdm09. We investigated incidence and clinical characteristics of influenza in children admitted to PICUs during the first three post-pandemic influenza seasons, using active screening.

Methods: We conducted a prospective surveillance study in 24 PICUs in Bavaria (Germany) from October 2010 to September 2013. Influenza cases among children between 1 month and 16 years of age admitted to these PICUs with acute respiratory infection were confirmed by PCR analysis of respiratory secretions.

Results: A total of 24/7/20 influenza-associated PICU admissions were recorded in the post-pandemic seasons 1/2/3; incidence estimates per 100,000 children were 1.72/0.76/1.80, respectively. Of all 51 patients, 80 % had influenza A, including 65 % with A(H1N1)pdm09. Influenza A(H1N1)pdm09 was almost absent in season 2 (incidence 0.11), but dominated PICU admissions in seasons 1 (incidence 1.35) and 3 (incidence 1.17). Clinical data was available for 47 influenza patients; median age was 4.8 years (IQR 1.6–11.0). The most frequent diagnoses were influenza-associated pneumonia (62 %), bronchitis/bronchiolitis (32 %), secondary bacterial pneumonia (26 %), and ARDS (21 %). Thirty-six patients (77 %) had underlying medical conditions. Median duration of PICU stay was 3 days (IQR 1–11). Forty-seven per cent of patients received mechanical ventilation, and one patient (2 %) extracorporeal membrane oxygenation; 19 % were treated with oseltamivir. Five children (11 %) had pulmonary sequelae. Five children (11 %) died; all had underlying chronic conditions and were infected with A(H1N1)pdm09. In season 3, patients with A(H1N1)pdm09 were younger than in season 1 (p = 0.020), were diagnosed more often with bronchitis/bronchiolitis (p = 0.004), and were admitted to a PICU later after the onset of influenza symptoms (p = 0.041).

(Continued on next page)
Conclusions: Active screening showed a continued high incidence of A(H1N1)pdm09-associated PICU admissions in the post-pandemic seasons 1 and 3, and indicated possible underestimation of incidence in previous German studies. The age shift of severe A(H1N1)pdm09 towards younger children may be explained by increasing immunity in the older paediatric population. The high proportion of patients with underlying chronic conditions indicates the importance of consistent implementation of the current influenza vaccination recommendations for risk groups in Germany.

Keywords: Influenza, Children, Intensive care, Post-pandemic.

Background

Influenza is one of the most common vaccine-preventable viral diseases, with the highest morbidity reported for children and elderly patients [1, 2]. Influenza infections during childhood usually present as mild respiratory upper airway disease, but severe complications and fatalities also occur, especially in children less than 2 years of age and in children with underlying chronic conditions [2–7]. However, 40–50 % of influenza-associated fatalities occur in previously healthy children [4, 8].

Before the influenza A(H1N1)pdm09 pandemic in 2009/2010, comparisons of clinical characteristics between patients infected with different influenza types (A vs. B) and between patients infected with different influenza A subtypes showed only small differences when controlling for age [9, 10]. During the pandemic, however, some studies observed increased morbidity and mortality among children compared to previous seasonal influenza [6, 11–13], while other studies described the clinical features of A(H1N1)pdm09 as being similar or even milder [14, 15]. Acute respiratory distress syndrome (ARDS) and fatal viral pneumonia was observed more frequently during the pandemic [16]. Post-pandemic surveillance was recommended, as circulation of A(H1N1)pdm09 was expected to continue for several years, gradually assuming a seasonal influenza pattern [16].

In Germany, influenza sentinel surveillance on outpatients of all ages [17] confirmed that the first post-pandemic season 2010/11 was dominated by influenza A(H1N1)pdm09 (62 %), co-circulating with influenza B (37 %) whereas A(H3N2) was rare (<1 %). During the second season 2011/12, A(H1N1)pdm09 was rare (1 %), whereas A(H3N2) was diagnosed in 75 % of cases and co-circulated with influenza B (24 %). In the third season 2012/13, all three types/subtypes co-circulated in similar proportions (34 % A(H1N1)pdm2009, 31 % A(H3N2), and 35 % B).

Information on the incidence and clinical characteristics of severe paediatric influenza resulting in intensive care treatment and/or fatal outcome is still limited in Germany, and post-pandemic data is thus far available only for the season 2010/11 [18–20]. Based on cases recorded by a nation-wide paediatric intensive care unit (PICU) reporting system, the pre-pandemic (2005/06–2007/08), pandemic (2009/10) and post-pandemic (2010/11) annual incidence of severe influenza cases per 100,000 children below 15 or 17 years of age was estimated as 0.05, 0.8–1.0, and 0.4, respectively [18–20]. The data so far available indicated a shift towards younger children in A(H1N1)pdm09 cases from the pandemic to the first post-pandemic season [20]. In these studies, it remained unclear whether the higher pandemic and post-pandemic incidence in children was caused by higher influenza activity, heightened physician awareness, more frequent or more sensitive influenza testing, or a more severe course of disease of A(H1N1)pdm09 [18]. Furthermore, all these previous studies may have been affected by underreporting, as influenza cases were reported at the discretion of the PICU physician without systematic screening for influenza in patients with severe acute respiratory infection.

In the study presented here, we used active screening to estimate the incidence of laboratory-confirmed influenza-associated PICU admissions in one of Germany’s largest federal states during the first three post-pandemic seasons. Furthermore, we described the clinical characteristics of influenza PICU patients and compared patients with severe A(H1N1)pdm09 disease between the post-pandemic seasons.

Methods

Study population and setting

Prospective, active surveillance was conducted in PICUs of paediatric hospitals in Bavaria, Germany. On December 31st, 2010 roughly 2,001,700 children <17 years of age were registered in Bavaria [21], representing 16 % of the German population in this age group [22]. The annual study population was defined as the sub-group of all children in Bavaria at least 1 month and <17 years of age.

All 30 paediatric hospitals in Bavaria equipped for paediatric intensive care treatment of children older than 1 month of age were invited to participate. These PICUs reported a total of 432 intensive care beds (median 14, IQR 11–16), including 207 beds (median 9, IQR 6–12) equipped with ventilation facilities.
Case definition and surveillance system
From October 2010 to September 2013 (season 1: Oct 2010–Sep 2011, season 2: Oct 2011–Sep 2012, season 3: Oct 2012–Sep 2013), all patients who fulfilled the following inclusion criteria were enrolled: i) admission to a participating PICU with suspected acute respiratory infection (ARI) of the upper or lower respiratory tract, with ARI-related symptoms (for example, coryza, cough, or sore throat); ii) age at PICU admission due to ARI at least 1 month and below 17 years of age; iii) parental written informed consent. Enrolled children with PCR-confirmed influenza were classed as influenza-associated ARI.

The PICU physician documented demographic characteristics, underlying chronic medical conditions, influenza vaccination status, diagnostic findings, ARI-associated diagnoses and complications, treatment, duration of hospital and PICU stay, and outcome in a structured questionnaire. A respiratory sample, usually a flocked nasopharyngeal or pharyngeal swab, was collected on the day of PICU admission for PCR-confirmation of influenza. Microbiological testing for bacteria or fungi was at the discretion of the PICU physician; pathogens detected at usually sterile sites or in tracheal aspirates were classified as bacterial or fungal co-infection.

PCR confirmation of influenza
PCR confirmation of influenza was performed either at the local laboratories of the participating PICUs using influenza-specific PCR, or (in the majority of cases) at the central laboratory at the Institute of Virology and Immunobiology of the University of Würzburg using multiplex PCR for respiratory viruses. For the latter, respiratory samples were placed in a viral transport medium (Mast Diagnostica GmbH, Reinfeld, Germany). At the central laboratory, they were tested using the commercial multiplex PCR ‘FTD® Respiratory pathogens 21’ (Fast Track Diagnostics, Luxembourg) to screen for respiratory viruses (sensitivity and specificity of 99–100% compared to singleplex PCR assays for all included viruses in clinical samples). Pathogens detected by the test kit included influenza A and B viruses, respiratory syncytial virus (RSV), parainfluenza virus (PIV) 1–4, coronavirus (CoV) NL63, OC43, HKU1, and 229E, human metapneumovirus (hMPV), human bocavirus (hBoV), adenovirus (AdV), rhinovirus (RhV), enterovirus (EV), parechovirus (PV), and additionally *Mycoplasma pneumoniae*. Samples positive for influenza A and B virus RNA in the multiplex PCR were further analysed to determine the subtype and lineage, respectively. Primers and probes specific for influenza A(H1N1)pdm09 were included in the ‘FTD Respiratory pathogens 21’ kit. All samples positive for influenza A virus RNA but negative for influenza A virus (H1N1)pdm09 RNA were tested by a PCR specific for influenza A virus H3.

Statistical analysis
All data was entered into a Microsoft Access database and transferred to IBM SPSS 21.0 for statistical analysis. Data was analysed descriptively (percentages, or median with inter-quartile range, IQR). Comparisons between groups were assessed for significance ($p < 0.05, \text{ two-sided}$) using Pearson’s Chi$^2$-test or Fisher’s Exact test for categorical data, and the Mann–Whitney $U$-test for continuous data.

The minimum incidence of influenza-associated PICU admissions per 100,000 children <17 years of age was calculated for each season based on the observed number of influenza PICU patients with a residential address in Bavaria. To correct for non-participating PICUs, the estimates of the total number of PICU influenza cases treated in all eligible PICUs in Bavaria per season were derived taking into account the annual percentage of participating PICUs. The annual study population was used as denominator.

A similar questionnaire and case definition had been used in previous studies on influenza-related PICU admission [18, 19]. Key variables were extracted from these publications for comparison purposes. Data from Streng et al. [18] and the present study were pooled for statistical comparison of pre- and post-pandemic seasons.

Ethical considerations
The study was approved by the Ethical Committee of the Medical Faculty, University of Würzburg, Germany.

Results
Participating PICUs and recruitment of ARI patients
During the 3-year-observation period, a total of 24 PICUs participated in the study (80% of the 30 eligible PICUs in Bavaria), with 20/14/17 PICUs participating in seasons 1/2/3 (67% /47 % /57 % of all eligible PICUs). Twelve of the 24 hospitals participated in all three seasons. Reasons stated for non-participation in all or single seasons were time limitations or staff shortages at the PICUs. Participating and non-participating PICUs did not differ significantly in the number of intensive care beds. The 24 participating PICUs enrolled a total of 572 (233/151/188) ARI patients (median 13, IQR 5–30).

Frequency of PICU patients with PCR-confirmed influenza, by type and subtype
Among the 572 enrolled PICU ARI patients, a total of 51 PCR-confirmed influenza patients (24/7/20 in seasons 1/2/3) were reported (Table 1). Influenza cases occurred between December 2010 and March 2011, between February and March 2012, and between December 2012 and April 2013, with 90.2% of all influenza patients admitted during the months January to March.
Of the 51 influenza patients, 41 (80.4 %) were confirmed by multiplex PCR, and 10 (19.6 %) by local PCR. Forty-one patients (80.4 %) were diagnosed with influenza A, and 10 (19.6 %) with influenza B (Table 1). Influenza A was subtyped as A(H1N1)pdm09 in 33 and as A(H3N2) in four patients; for four further patients, the A subtype was not available or indeterminate. The frequency of influenza types/subtypes differed strongly between observation years (Table 1). Type A was diagnosed in 96 %/29 %/80 % of PICU patients with PCR-confirmed influenza in seasons 1/2/3, respectively, including 79 %/14 %/65 % patients with A(H1N1)pdm09. Influenza B was the dominating type in season 2 (71.4 %).

Incidence estimates for influenza-associated PICU admittance

Based on the observed cases, the minimum incidence for PCR-confirmed influenza-associated PICU admission per 100,000 children <17 years of age in Bavaria was calculated as 1.15/0.36/1.03 for seasons 1/2/3, respectively. Taking into account that the observed cases were based on data from 67 %/47 %/57 % of all eligible PICUs, the total number of influenza-associated PICU admissions in Bavaria was estimated and corrected incidences were calculated as 1.72/0.76/1.80 per 100,000 children <17 years. Subtype-specific corrected incidences were 1.35/0.11/1.17 for A(H1N1)pdm09, 0.0/0.11/0.27 for A(H3N2), and 0.07/0.54/0.36 for B.

Clinical characteristics of influenza-associated PICU admissions

Demographic characteristics, hospital admittance and length of stay

For 47 (92.2 %) of the 51 PCR-confirmed influenza PICU patients, questionnaires with clinical data were available (23/6/18 in seasons 1/2/3, respectively). Eighty-five per cent of these were diagnosed with influenza A, including 68 % with A(H1N1)pdm09, and 15 % with influenza B. Sixty per cent were male; median age was 4.8 years, with 51.1 % of children <5 years and 23.4 % <1 year of age (Table 2).

After onset of ARI symptoms, children were admitted to hospital after a median interval of 3.0 days; 83 % were transferred to the PICU on the day of hospital admission or the following day (Table 2). Two long-term hospitalized children (4.2 %) required PICU treatment due to ARI and were diagnosed with suspected nosocomial influenza A(H1N1)pdm09 infection. Median length of PICU stay was 3.0 days and median length of total hospital stay was 7.5 days (Table 2).

Underlying chronic conditions

Underlying chronic medical conditions were reported for a total of 36 influenza PICU patients (76.6 %) (Table 3). Chronic neurological diseases were most frequent (34.0 %), followed by chronic lung disease (25.5 %), preterm birth (21.3 %), cardiac malformations (17.0 %), obesity (10.6 %), genetic disorders (8.5 %), and immunocompromising conditions (8.5 %).

Influenza vaccination status

Of 36 influenza PICU patients with underlying chronic conditions, four (11.1 %) were too young (<6 months of age) to have been immunized against influenza, and for two patients (5.6 %), data on their influenza vaccination status was unavailable. Twenty-nine (80.6 %) patients from this risk group had not been vaccinated against influenza although they would have been eligible. One immunocompromised child (2.8 %) had been vaccinated in October 2012, but was diagnosed with A(H3N2) in January 2013.

Clinical diagnoses

One or more specific influenza-associated diagnoses/complications were reported for 42 (89.4 %) of the 47 children (Table 4). The most frequent diagnosis was influenza-associated pneumonia (61.7 %), followed by bronchitis/bronchiolitis (31.9 %), and secondary bacterial pneumonia (25.5 %). ARDS was reported for 10 (21.3 %) and sepsis for six children (12.8 %); other complications were rare.
Thirty-nine of the 47 patients (83.0%) underwent a chest radiograph.

Co-infections

In addition to influenza, laboratory-confirmed co-infections were reported for 16 children (34.0% out of 47). Of these, seven (14.9%) had viral, five (10.6%) bacterial, one (2.1%) viral/bacterial, two (4.3%) viral/fungal, and one (2.1%) bacterial/fungal co-infections. The most frequent co-infecting virus was RSV (seven children).

Microbiological testing was documented for 33 patients (70.2%), with pathogens detected in usually sterile

### Table 2

Demographic characteristics and details on PICU/hospital admission of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 47)*

| Characteristics                                      | Influenza type/subtype | Comparison of seasons |
|-------------------------------------------------------|------------------------|-----------------------|
|                                                       | All patients | A (H1N1)pdm09 | A(H3N2) | A (subtype n.a.) | B | S1 vs S3 | p-value* |
| Gender; n (%)                                         | N = 47     | N = 40       | N = 32   | N = 2         | N = 7 |          |          |
| Male sex; n (%)                                       | 28 (59.6)  | 24 (60.0)   | 18 (56.3) | 3 (75.0)  | 4 (75.0) | 4 (57.1) | 0.481    |
| Age at ICU admission, in years (median, IQR)          | 4.8 (1.6–11.0) | 4.7 (1.1–11.1) | 5.4 (1.6–11.3) | 0.9 (0.6–4.4) | 4.9 (2.3–10.4) | 5.0 (2.3–9.4) | 0.020    |
| Interval between onset of ARI symptoms and ICU admission, in days (median, IQR)³ | 3.0 (2.0–5.3) | 3.0 (1.0–6.0) | 3.5 (1.0–5.8) | 2.5 (2.0–10.5) | 3.0 (n.a.) | 3.0 (1.5–5.0) | 0.041 |
| Duration of ICU stay, in days (median, IQR)            | 3.0 (1.0–5.0) | 3.0 (1.0–5.0) | 3.0 (1.0–5.0) | 2.5 (2.0–4.5) | 2.0 (n.a.) | 3.0 (1.5–4.0) | 0.217 |
| Duration of hospital stay, in days (median, IQR)       | 7.5 (4.0–16.3) | 8.0 (4.0–16.0) | 7.0 (4.0–16.0) | 11.0 (8.8–59.0) | 13.0 (7.3–20.3) | 5.0 (3.0–22.0) | 0.953 |

n.a. not available, vs versus
*Fisher’s Exact Test or Mann–Whitney U-test, respectively
*Clinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
³Date of ARI symptom onset missing for nine patients
²Comparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)

### Table 3

Underlying chronic medical conditions of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 47)*

| Underlying medical conditions | Influenza type/subtype | Comparison of seasons |
|-------------------------------|------------------------|-----------------------|
|                               | All patients | A (H1N1)pdm09 | A(H3N2) | A (subtype n.a.) | B | S1 vs S3 | p-value* |
| At least one medical condition; n (%) | N = 47     | N = 40      | N = 32   | N = 4         | N = 7 |          |          |
| Neurological disease; n (%)   | 16 (34.0)  | 14 (35.0)  | 13 (40.6) | 1 (25.0)  | 0 (0.0) | 2 (28.6) | 1.000    |
| Chronic lung disease; n (%)   | 12 (25.5)  | 12 (30.0)  | 11 (34.4) | 0 (0.0)  | 1 (25.0) | 0 (0.0) | 1.000    |
| Pre-term birth; n (%)         | 10 (21.3)  | 9 (22.5)   | 8 (25.0)  | 1 (25.0)  | 0 (0.0) | 1 (14.3) | 0.210    |
| Cardiac malformation; n (%)   | 8 (17.0)   | 8 (20.0)   | 3 (9.4)   | 3 (75.0)  | 2 (50.0) | 0 (0.0) | 0.558    |
| Obesity; n (%)                | 5 (10.6)   | 5 (12.5)   | 3 (9.4)   | 0 (0.0)  | 2 (50.0) | 0 (0.0) | 0.245    |
| Genetic disorder; n (%)       | 4 (8.5)    | 3 (7.5)    | 3 (9.4)   | 0 (0.0)  | 0 (0.0) | 1 (14.3) | 0.558    |
| Immunocompromised; n (%)      | 4 (8.5)    | 2 (5.0)    | 0 (0.0)   | 1 (25.0) | 1 (25.0) | 2 (28.6) | n.a.     |
| Renal disease; n (%)          | 1 (2.1)    | 1 (2.5)    | 1 (3.1)   | 0 (0.0)  | 0 (0.0) | 0 (0.0) | 0.419    |
| Other underlying conditions; n (%) | 9 (19.1)  | 8 (20.0)  | 5 (15.6)  | 2 (50.0) | 1 (25.0) | 1 (14.3) | 0.134    |

n.a. not available, vs versus
*Fisher’s Exact test or Mann–Whitney U-test, respectively
*Clinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
³Including asthma, broncho-pulmonary dysplasia, other chronic lung disease
²Comparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)
material from two patients (Escherichia coli (1), Candida sp. (1)) and from tracheal aspirates of seven intubated patients (Candida sp. (2), Pseudomonas aeruginosa (2), Streptococcus sp. (2), Enterococcus faecium (1), Escherichia coli (1) and Moraxella catarrhalis (1)).

**Patient treatment and outcome**
The majority of the 47 PICU patients were treated intravenously with antibiotics (72.3 %), and with antipyretics (70.2 %) (Table 5). Thirteen children (27.7 %) received antiviral treatment, including nine (19.1 %) patients

---

### Table 4 Diagnoses/complications of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 47)^a

| Complications                                      | All patients | A(H1N1)pdm09 | A(H3N2) | A (subtype n.a.) | B | Comparison of seasons |
|---------------------------------------------------|--------------|--------------|---------|------------------|---|-----------------------|
|                                                   | N = 47       | N = 40       | N = 32  | N = 4            | N = 7 | S1 vs S3 p-value*     |
| At least 1 specific complication; n (%)           | 42 (89.4)    | 36 (90.0)    | 29 (90.6) | 3 (75.0)         | 4 (100.0) | 6 (85.7) 0.497       |
| Influenza-associated pneumonia; n (%)             | 29 (61.7)    | 26 (65.0)    | 22 (68.8) | 1 (25.0)         | 3 (75.0) | 3 (42.9) 1.000       |
| Bronchitis/bronchiolitis; n (%)                   | 15 (31.9)    | 13 (32.5)    | 8 (25.0)  | 3 (75.0)         | 2 (50.0) | 2 (28.6) 0.004       |
| Secondary bacterial pneumonia; n (%)             | 12 (25.5)    | 10 (25.0)    | 10 (31.3) | 0 (0.0)          | 0 (0.0)  | 2 (28.6) 0.452       |
| ARDS; n (%)                                       | 10 (21.3)    | 9 (22.5)     | 7 (21.9)  | 2 (50.0)         | 0 (0.0)  | 1 (14.3) 0.099       |
| Sepsis; n (%)                                     | 6 (12.8)     | 6 (15.0)     | 4 (12.5)  | 1 (25.0)         | 1 (25.0) | 0 (0.0) 1.000        |
| Febrile convulsions; n (%)                        | 3 (6.4)      | 2 (5.0)      | 2 (6.3)   | 0 (0.0)          | 0 (0.0)  | 1 (14.3) 1.000       |
| Encephalitis/encephalopathy; n (%)                | 1 (2.1)      | 1 (2.5)      | 1 (3.1)   | 0 (0.0)          | 0 (0.0)  | 0 (0.0) 1.000        |
| Laryngitis/pseudocroup; n (%)                     | 1 (2.1)      | 1 (2.5)      | 1 (3.1)   | 0 (0.0)          | 0 (0.0)  | 0 (0.0) 1.000        |
| Other; n (%)                                       | 6 (12.8)     | 5 (12.5)     | 5 (15.6)  | 0 (0.0)          | 0 (0.0)  | 1 (14.3) 1.000       |

n.a. not available, vs versus, i.v. intravenous

---

### Table 5 Treatment and outcome of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 47)^a

| Treatment                          | All patients | A(H1N1)pdm09 | A(H3N2) | A (subtype n.a.) | B | Comparison of seasons |
|------------------------------------|--------------|--------------|---------|------------------|---|-----------------------|
|                                    | N = 47       | N = 40       | N = 32  | N = 4            | N = 7 | S1 vs S3 p-value*     |
| Antiviral drugs^b; n (%)           | 13 (27.7)    | 12 (30.0)    | 9 (28.1) | 1 (25.0)         | 2 (50.0) | 1 (14.3) 1.000       |
| Antibiotics i.v.; n (%)            | 34 (72.3)    | 31 (77.5)    | 25 (78.1) | 2 (50.0)         | 4 (100.0) | 3 (42.9) 0.676       |
| Antipyretics; n (%)                | 33 (70.2)    | 28 (70.0)    | 22 (68.8) | 2 (50.0)         | 4 (100.0) | 5 (71.4) 0.452       |
| Catecholamines; n (%)              | 13 (27.7)    | 13 (32.5)    | 11 (34.4) | 1 (25.0)         | 1 (25.0) | 0 (0.0) 1.000        |
| Inhalation therapy; n (%)          | 13 (27.7)    | 13 (32.5)    | 11 (34.4) | 2 (50.0)         | 0 (0.0)  | 0 (0.0) 1.000        |
| Oxygen; n (%)                      | 31 (66.0)    | 28 (70.0)    | 20 (62.5) | 4 (100.0)        | 4 (100.0) | 3 (42.9) 0.275       |
| Intratracheal ventilation; n (%)   | 15 (31.9)    | 14 (35.0)    | 12 (37.5) | 1 (25.0)         | 1 (25.0) | 1 (14.3) 1.000       |
| CPAP; n (%)                        | 11 (23.4)    | 9 (22.5)     | 7 (21.9)  | 0 (0.0)          | 2 (50.0) | 2 (28.6) 0.084       |
| Other; n (%)                       | 14 (29.8)    | 13 (32.5)    | 10 (31.3) | 2 (50.0)         | 1 (25.0) | 1 (14.3) 0.247       |
| Outcome                            |              |              |         |                  |     |                      |
| Sequelae; n (%)                    | 5 (10.6)     | 4 (10.0)     | 3 (9.4)   | 1 (25.0)         | 0 (0.0)  | 1 (14.3) 0.548       |
| Death; n (%)                       | 5 (10.6)     | 5 (12.5)     | 5 (15.6)  | 0 (0.0)          | 0 (0.0)  | 0 (0.0) 1.000        |

n.a. not available, vs versus, i.v. intravenous

---

^aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients

^bComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)

^cOther complications, excluding the pre-defined complications otitis media, status asthmaticus, and myocarditis (for these pre-defined complications, no case was reported)
treated with oseltamivir (four patients received acyclovir, and one patient ganciclovir and valgancyclovir due to other reasons). The median delay between onset of ARI symptoms and oseltamivir treatment was 3.5 days (range 0 to 10 days), with three children receiving treatment within 2 days after symptom onset. Oseltamivir treatment was associated with the presence of a viral or other co-infection ($p = 0.045$), and with a longer stay at the PICU (median 11 days, IQR 2.5–27.5; $p = 0.043$). Thirteen (27.7 %) children each were treated with catecholamines and with inhalation therapy, mainly with bronchodilators. A total of 22 children (46.8 %) required mechanical ventilation; of these, 11 (23.4 %) received only intratracheal ventilation, seven (14.9 %) only CPAP, and four (8.5 %) both. One child (2.1%) with an immunosuppressed condition, infected with influenza A(H3N2), RSV, Epstein-Barr virus and Candida sp., was treated with extracorporeal membrane oxygenation (ECMO).

**Fatalities and sequelae**

Five children (10.6 %), infected with A(H1N1)pdm09, died at an age of 4 to 11 years; four were male patients (Table 6). Four of these children suffered both from severe neurological conditions (two children with previous peripartal asphyxia and spastic tetraparesis; one child with cerebral paresis and tetraparesis; one child with congenital cerebral disorder), and from chronic pulmonary conditions; two of these four children were also born pre-term. Influenza-associated pneumonia was diagnosed in all four of these children; three additionally had secondary bacterial pneumonia, and one child also developed sepsis. For the fifth child, obesity was reported as the only risk factor; and sepsis and suspected encephalitis as complications. Bacterial co-pathogens were detected in three of these five children and suspected in one child; two viral and two fungal co-infections were also reported. All five children received intratracheal ventilation, antibiotics and catecholamines; two were additionally treated with antiviral medication. Death occurred 1, 2, 4, 19, and 26 days after PICU admission, with ARDS reported as cause of death in three children.

Sequelae were reported for five patients (10.6 %): state after surgery due to pleural effusion/empyema in two children; increased oxygen requirements in two children who had previously already received oxygen therapy at home; damage of the lung after high-pressure ventilation in one child.

**Comparison of PICU patients infected with influenza A(H1N1)pdm09 in the first and the third post-pandemic season**

Influenza A(H1N1)pdm09 from season 1 ($n = 18$) were compared to patients from season 3 ($n = 13$) (Tables 2, 3, 4, 5). Patients with influenza A(H1N1)pdm09 were significantly older in season 1 (median 7.1, IQR 3.3–12.5) than in season 3 (median 1.7; IQR 0.1–8.3; Table 2). Figure 1 shows the difference in age distribution between both seasons, and the high proportion of children below 2 years of age as opposed to low proportions in all other age groups in season 3. After onset of symptoms, children were admitted to a PICU after a significantly shorter period, with a median of 3 days (IQR 1–4) in season 1 compared to 6 days (IQR 2.0–7.5) in season 3 (Table 2). In season 1, significantly fewer children were diagnosed with bronchitis/bronchiolitis (Table 4), and they tended to require CPAP treatment less frequently than in season 3 (11.1 % vs. 41.7 %, $p = 0.084$, Table 5).

**Comparison of PICU patients infected with influenza in pre-pandemic and post-pandemic seasons**

In the pre-pandemic period, median duration of PICU stay was longer (19 days), and children were more often diagnosed with encephalitis/encephalopathy (25%) and co-infections (65 %) than in later periods (Table 7). The proportion of children with influenza-associated pneumonia was highest (74 %) during the pandemic, whereas secondary bacterial pneumonia (17 %), bronchitis/bronchiolitis (12 %) and sepsis (6 %) were reported less frequently during the pandemic than in the pre- and post-pandemic seasons. Oseltamivir treatment decreased significantly in the post-pandemic period (Table 7).

**Discussion**

During the first three post-pandemic seasons 2010/11, 2011/12 and 2012/13, active screening of children with acute respiratory infection admitted to 24 paediatric intensive care units in Bavaria identified a total of 51 PCR-confirmed influenza cases, resulting in annual incidence estimates of 1.7, 0.7, and 1.8 influenza-associated PICU admissions per 100,000 children, respectively. These figures would, by extrapolation, correspond to a total number of 559 children with influenza-associated PICU admission in Germany within the 3-year post-pandemic period, with an annual average of 186 children. This is almost 28 times as high as the annual average of six to seven influenza-associated PICU admissions detected by nation-wide PICU surveillance in Germany during three pre-pandemic years without active screening [18]. Furthermore, the incidence estimates for the subtype A(H1N1)pdm09 derived from our active screening study were higher in the first and third post-pandemic seasons (1.35 and 1.17, respectively) than previous incidence estimates for PICU patients in the pandemic (0.8–1.0) and the first post-pandemic (approximately 0.4) season in Germany [19, 20]. Thus, our results indicate possible underreporting in previous studies, and show a continued high level of A(H1N1)pdm09-associated PICU admissions even 3 years after the pandemic.
Table 6: Fatalities in five out of 47 patients with PCR-confirmed influenza in Bavarian PICUs, 2010–2013

| Patient | PICU admittance (season) | Age (years) | Influenza type/subtype | Co-pathogen(s) detected\(^a\) | Underlying chronic condition | Influenza vaccination | Complications | Antiviral treatment (days) | Antibiotics i.v. (days) | Cause of death |
|---------|--------------------------|-------------|------------------------|-------------------------------|-------------------------------|-----------------------|---------------|---------------------------|------------------------|-----------------|
| 1       | 2010/11                  | 10          | A(H1N1)pdm09           | Escherichia coli              | Obesity                       | No                    | ARDS, sepsis, convulsion (encephalitis suspected) | Acyclovir (2) | Yes (2) | ARDS, Sepsis |
| 2       | 2010/11                  | 4           | A(H1N1)pdm09           | Streptococcus sp., Candida sp. | Neurologic Pulmonary Pre-term birth | No                    | Pneumonia, secondary bacterial pneumonia, pleural effusion | No | Yes (10) | Circulatory insufficiency |
| 3       | 2010/11                  | 4           | A(H1N1)pdm09           | RSV Pseudomonas aeruginosa     | Neurologic Pulmonary Pre-term birth | No                    | Pneumonia, secondary bacterial pneumonia, ARDS | No | Yes (19) | ARDS |
| 4       | 2012/13                  | 11          | A(H1N1)pdm09           | RSV, Candida sp.              | Neurologic Pulmonary          | No                    | Pneumonia, secondary bacterial pneumonia, bronchitis, ARDS, sepsis | Oseltamivir (5) | Yes (22) | ARDS, circulatory insufficiency |
| 5       | 2012/13                  | 11          | A(H1N1)pdm09           | None                          | Neurologic Pulmonary          | No                    | Pneumonia            | No | Yes (4) | Respiratory failure |

\(^a\)Viral co-infections were detected either by local PCR or central multiplex PCR; bacteria and fungi were identified from blood culture or tracheal aspirates (intratracheal ventilation)
In our study, the proportions of children with bacteria-associated complications (secondary bacterial pneumonia, sepsis) were similar to the proportions observed during the pre-pandemic period, but appeared higher than those observed during the pandemic 2009/10 [19]. The lower proportions observed during the pandemic might be explained by the time shift of the peak of influenza cases, which was observed as early as November 2009 in Germany [19]. Thus, the pandemic influenza peak did not coincide with the seasonal peak of Streptococcus pneumoniae, the bacterial pathogen most frequently associated with community-acquired influenza [23].

Antiviral treatment patterns changed considerably during the post-pandemic period, with a decrease in the proportion of paediatric influenza cases receiving oseltamivir from previously 50 % [18] and 61 % [19] to 19 %. Oseltamivir is considered to be most advantageous when administered within the first 48 h of influenza disease. The reduced use in the post-pandemic period may therefore be partly due to the fact that median time between onset of influenza symptoms and PICU admission was longer than during the pandemic (3 vs. 2 days [19]). Increasing uncertainty regarding the effectiveness of oseltamivir in the treatment of paediatric influenza may also have played a role [24, 25]. Post-pandemic oseltamivir treatment was associated with co-infections and longer PICU stay, suggesting that it were mainly children with severe complications or with serious underlying conditions who received this medication.

In our study, about two-thirds of influenza cases and all fatalities were A(H1N1)pdm09-associated. During the post-pandemic seasons 1/2/3, the proportion of A(H1N1)pdm09 cases among the PICU patients was 79 %/14 %/65 % and, thus, considerably higher than the proportion of this subtype reported among outpatients by national influenza surveillance (65 %/1 %/34 %) [17]. This observation suggests that A(H1N1)pdm09 may be associated more often with a severe course of influenza requiring PICU treatment than other influenza types/subtypes. Similar observations on the proportion of A(H1N1)pdm09-associated PICU admissions have been reported in the United States [9].

Comparison of PICU patients with A(H1N1)pdm09 between the post-pandemic seasons showed that median age was 1.7 years in the third season and, thus, significantly lower than in the first season. A significant age shift towards younger children, from a median age of 5 to 3 years, had already been observed in a comparison of the pandemic and the first post-pandemic season in Germany [20]. The continued shift towards younger patients in the third season is likely to be due to increasing immunity in the older paediatric population, after previous contact with A(H1N1)pdm09. Seroprevalence data from Germany had already shown evidence for A(H1N1)pdm09 infection in as many as 25 % of children aged 1–4 years and 48 % of 5–17 year-old children for the pandemic season 2009/10 [26]. A similar shift towards younger hospitalized children [27, 28] and towards younger children with severe paediatric A(H1N1)pdm09-associated influenza from the pandemic season to the first post-pandemic season had also been detected in other European countries [28–31].

In Germany, paediatric influenza vaccination for pandemic influenza A(H1N1)pdm09 was recommended and funded for all children as monovalent vaccination from October 2009 to July 2010 [32]. For seasonal influenza, however, paediatric influenza vaccination was and is currently recommended only for specific risk groups with underlying chronic conditions [33]. Vaccination uptake was low, even in this target group. Pre-pandemic vaccination rates were 5 % for all children and about 15 % for children with chronic underlying conditions in 2007/2008 [34]. For the pandemic and post-pandemic seasons, no data on vaccination rates is available for children, but vaccination rates as low as 14 % (2009/10) and 11 % (2010/11) were reported for adults, with a vaccination rate of only 17 % even for risk group adults [35]. In our study, more than 75 % of influenza-associated PICU patients were children with underlying chronic conditions. Analysis of their reported influenza
vaccination status showed that among these were a high proportion of vaccine-eligible but unvaccinated children. Patients with chronic conditions too young to be vaccinated and other paediatric risk groups, such as otherwise healthy children below 2 years of age, are not covered by the current German recommendation. All these groups could profit considerably from universal influenza vaccination for children, either directly or by herd protection. In contrast to the situation in Germany, in the United States universal influenza vaccination for all children older than 6 months of age has been established, and vaccination coverage reached a level of approximately 41 % in 2013 [36]. Compared to 348 influenza-associated paediatric deaths observed in the United States during the pandemic 2009/10, only 79 were observed in the strong A(H1N1)pdm09 season 2013/14 [37]. This might partly be explained by increasing immunity in children after previous A(H1N1)pdm09 infection, but may in part also be a result of the influenza vaccination program [37]. In England, a universal childhood vaccination programme with a new live attenuated influenza vaccine (LAIV) with intra-nasal application was started in the 2013/14 influenza season [38]. First results showed an overall uptake of 53 % in primary school aged children, indicating a good acceptance of LAIV, and suggesting direct and indirect impacts on disease incidence, including reduction of paediatric influenza-associated hospitalisations.

To our knowledge, our study is the first in Europe to investigate paediatric influenza in PICU patients during the first three post-pandemic seasons after the 2009/10 pandemic. The strengths of our study include the multi-centre design covering the majority of PICUs in Bavaria, the active screening for influenza in patients admitted to PICUs, and PCR-confirmation of all influenza cases. A limitation is that the corrected incidence estimates were based on the assumption that participating and non-participating PICUs treated a similar number of severe paediatric influenza patients. Although PICUs of both groups were of similar size, some of the non-participating PICUs, where paediatricians indicated lack of time as reason for non-participation, may have treated a higher number of patients, or patients with higher acuity. Further limitations include potential over- and underreporting in participating PICUs. On the one hand, due to different hospitalization rules some children may have been admitted to PICUs mainly for the purpose of monitoring their course of influenza disease more closely, thus resulting in an overestimate of severe cases. On the other hand, some parents of children with severe influenza may have refused study participation, or children with a fulminant course of influenza disease may have died before they were admitted to a PICU [4]. Thus, the high incidence estimates derived in this study may still underestimate the true burden of severe influenza.

Table 7 Summary of key variables from studies of PICU-associated influenza in Germany, 2005–2013. Data were collected in Germany during the pre-pandemic period 2005/06–2007/08 [18], in Germany during the pandemic season 2009/10 [19], and in Bavaria (Southern Germany) during the post-pandemic period 2010/11–2012/13 (this study).

| Key variables of PICU patients | Pre-pandemic (2005/06–2007/08) | Pandemic (2009/10) | Post-pandemic (2010/11–2012/13) | Pre-pandemic vs. post-pandemic | p-value |
|-------------------------------|---------------------------------|-------------------|-------------------------------|-------------------------------|---------|
| N = 20                        | N = 89a                         | N = 47            |                               |                               |         |
| Male sex; n (%)               | 12 (60)                         | 56 (60)           | 28 (60)                       | 1.000                         |         |
| Age at ICU admission, in years (median, IQR) | 7.5 (0.5–12.75) | 4.5 (1.3–9.3) | 4.8 (1.6–11.0) | 0.727                         |         |
| Duration of ICU stay, in days (median, IQR) | 19 (12–38) | 8 (3–17) | 3 (1–11) | 0.006                         |         |
| Chronic underlying conditions; n (%) | 11 (53) | 63 (74) | 36 (77) | 0.089                         |         |
| Complications/diagnoses       |                                 |                   |                               |                               |         |
| Influenza-associated pneumonia; n (%) | 12 (60) | 66 (74) | 29 (62) | 1.000                         |         |
| Bronchitis/bronchiolitis; n (%) | 6 (30) | 11 (12) | 15 (32) | 1.000                         |         |
| Secondary bacterial pneumonia; n (%) | 5 (25) | 15 (17) | 12 (26) | 1.000                         |         |
| ARDS; n (%)                   | 5 (25)                          | 22 (25)           | 10 (21)                       | 0.756                         |         |
| Sepsis; n (%)                 | 3 (15)                          | 5 (6)             | 6 (13)                        | 1.000                         |         |
| Encephalitis/encephalopathy; n (%) | 5 (25) | 6 (7) | 1 (2) | 0.008                         |         |
| Co-infections; n (%)          | 13 (65)                         | n.a.              | 16 (34)                       | 0.030                         |         |
| Oseltamivir treatment; n (%)  | 10 (50)                         | 51 (61)           | 9 (19)                        | 0.017                         |         |
| Mechanical ventilation; n (%) | 10 (50)                         | 56 (65)           | 22 (47)                       | 1.000                         |         |
| Death; n (%)                  | 2 (10)                          | 11 (12)           | 5 (11)                        | 1.000                         |         |
| Influenza A(H1N1)pdm09; n (%) | 0 (0)                           | 89 (100)          | 32 (68)                       | <0.001                         |         |

a 89 cases with PICU treatment; proportions may refer to slightly lower patient numbers, see Altmann et al. 2011 [19]
b Key data from this study were pooled with data from Streng et al. 2011 [18] and compared using Fisher’s Exact test or Mann–Whitney U-test, respectively.
Conclusions
The incidence estimates of influenza A(H1N1)pdm09-associated PICU admissions, derived from active screening of PICU patients with acute respiratory infections, reached similarly high levels in the first and third post-pandemic seasons. Both incidence estimates were higher than those previously reported by nation-wide PICU surveillance for the pandemic and the first post-pandemic season, suggesting possible underreporting in previous studies without active screening. Comparison of the first and third post-pandemic seasons indicated an age shift of severe A(H1N1)pdm09 towards younger children, which might be explained by increasing immunity in the older paediatric population. The large proportion of children with underlying chronic conditions indicates the need for a more consistent implementation of the current recommendations for influenza vaccination of specific risk groups in Germany. These children could also profit from herd protection, if universal influenza vaccination was successfully introduced in Germany.

Abbreviations
AdV: adenovirus; ARDS: acute respiratory distress syndrome; ARI: acute respiratory infection; CoV: coronavirus; CPAP: continuous positive airway pressure; ECMO: extracorporeal membrane oxygenation; EV: enterovirus; hBoV: human bocavirus; hMPV: human metapneumovirus; ICU: intensive care unit; IQR: inter-quartile range; i.v.: intravenous; PCR: polymerase chain reaction; PICU: paediatric intensive care unit; PV: parainfluenza virus; PV: parechovirus; RhV: rhinovirus; RSV: respiratory syncytial virus; sp.: species.

Competing interests
AS and JGL received grants for studies, lecturing fees or travelling grants from GlaxoSmithKline (AS, JGL) and other vaccine manufacturers (Sanofi Pasteur MSD (AS, JGL), Novartis Vaccines and Diagnostics (AS, JGL), AstraZeneca (JGL), Pfizer (JGL), and CSL Behring (JGL)). BW and CP report no competing interest.

Authors’ contributions
AS designed the study, coordinated data collection, performed the analysis, interpreted the data, and drafted the manuscript. BW and CP performed multiplex PCR and subtyping on laboratory specimens, interpreted virological data, and revised the manuscript. JGL supervised the study, supported data interpretation, and revised the manuscript. The clinical data were collected by the Bavarian PICU Study Group on Influenza and Other Viral ARI, from Oct 2010 to September 2013. All authors read and approved the final manuscript.

Acknowledgements
The authors thank all participating hospitals, and PICU and university staff involved in data collection and virological testing. Karin Seeger we thank for helpful comments on the manuscript. The study was supported by an unrestricted grant from GlaxoSmithKline GmbH & Co. KG, Munich, Germany. Apart from financial support, the company was not involved in any part of the study. The publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.

Bavarian PICU Study Group on Influenza and Other Viral ARI
Participants and their affiliations while participating during the study period October 2010 to September 2013: Nadja Bösel, Petra Gašpírová, Katharina Heinrich, Angela Hösl, Maximilian Klein, Alexander Schnelke (Klinikum St. Marien Amberg, Klinik für Kinder und Jugendliche; Amberg); Christian Weg (Klinikum Aschaffenburg, Klinik für Kinder- und Jugendmedizin; Aschaffenburg); Harry Steinherr (Klinikum Augsburg, Klinik für Kinder und Jugendliche; Augsburg); Hans-Georg Schreiner, Sibylle Horsinka (Klinik Josefínům, Kinderkrankenhaus; Augsburg); Alfons Wolf (Klinikum Sozialstiftung Bamberg, Kinderklinik; Bamberg); Engelke, Wolfgang Pohl (Klinikum Bayreuth GmbH, Kinderklinik; Bayreuth); Barbara Boblein, Kerstin Egler, Katharina Glas, Annegret Iven, Christine Leistner, Lena Lippert, Radhika Kothari, Chaitidou Panagiota, Daniela Rettner, S. Thomaschewski, Annika Weigelt, Beatrix Wenzel, Florian Zapf (Regiomed-Kliniken gGmbH, Klinik für Kinder- und Jugendmedizin; Coburg); Gerlinde Stuber (DONAUASAR Klinikum Deggendorf, Kinder- und Jugendmedizin; Deggendorf); Michael Schroot, Hans-Georg Topf (Universitätsklinikum Erlangen, Kinder- und Jugendklinik; Erlangen); Herbert Steigenberger (Klinikum Fürth, Klinik für Kinder und Jugendliche; Fürth); Makotowa, Rolf Ponsader (Sanà Klinikum Hof GmbH, Kinderklinik; Hof); Oliver Götz (Klinikum Kempten-Oberallgäu, Kinderklinik; Kempten); Heinrich Eberhardt, Andrea Quitteker (Kinderkrankenhaus St. Marien, Abteilung für Kinder- und Jugendmedizin; Landshut); Angelo A 4. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al. Influenza-vaccination was successfully introduced in Germany.

References
1. Heikkinen T. Influenza in children. Acta Paediatr. 2006;95:778–84.
2. Poehling KA, Edwards KD, Weinberg GA, Solisay F, Sta et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31–40.
3. Quach C, Picah-Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics. 2003;112:197–201.
4. Wong NK, Inam S, Blanton L, Dhara R, Bramer L, Fry AM, et al. Influenza-associated pediatric deaths in the United States, 2004–2012. Pediatrics. 2013;132:796–804.
5. Gill PJ, Ashdown HF, Wang K, Heneghan C, Roberts NW, Hamden A, et al. Identification of children at risk of influenza-related complications in primary ambulatory care: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:139–49.
6. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. Eur J Pediatr. 2014;173:365–75.
7. Neuvi KM, Wright PF, Miller JR, EF, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856–64.
8. Louie JK, Schechter R, Horan and S, Guevara H, Shoemaker TR, Madrigal NY, et al. Severe paediatric influenza in California, 2003–2005: implications for immunization recommendations. Pediatrics. 2006;117:e610–8.
9. Chaves SS, Aragon D, Bennett N, Cooper T, D’Mello T, Farley M, et al. Patients hospitalized with laboratory-confirmed influenza during the 2010–2011 influenza season: exploring disease severity by virus type and subtype. J Infect Dis. 2013;208:305–14.
10. Glezen WP, Schimler JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(6):e43–51.
11. Bagdure D, Curtis DJ, Dobyns E, Gliede MP, Dominguez SR. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. PLoS One. 2010;5(12):e15173.
12. Sadows J, Centeno MA, Garcia MD, Boada NB, Lattini BE, Motto EA, et al. Influenza A (H1N1) infection in children admitted to a pediatric intensive care unit: differences with other respiratory viruses. Pediatr Crit Care Med. 2011;12:e36–40.
13. Weeling A, Benser J, Kohlhauser-Vollmuth C, Weischbrich B, Streng A, Liese JG. Clinical characteristics of pediatric hospitalizations associated with influenza A (H1N1) in Northern Bavaria. Germany. BMC Res Notes. 2012;5:304.
14. Debiaggi M, Candelucchi F, Ceresola ER, Clementi M. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. ViroL J. 2012;9:247.
15. Heininger U, Baer G, Ryser A-J, Li Y. Comparative analysis of clinical characteristics of pandemic influenza A/H1N1 and seasonal influenza A infections in hospitalized children. Pediatr Infect Dis J. 2013;32:293–6.
16. European Centre for Disease Prevention and Control (ECDC). Forward look risk assessment – Likely scenarios and uncertainties in the 2010/2011 influenza season in Europe and beyond. Stockholm, October 2010. http://www.ecdc.europa.eu/en/healthtopics/H1N1/Documents/1003_RA_forward_look_influenzapdf. Accessed 08 Dec 2015.
17. Robert Koch-Institut. Arbeitsgemeinschaft Influenza. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2012/13. Berlin 2013. http://influenza.rki.de/Saisonberichtasp. Accessed 08 Dec 2015.
18. Streng A, Grote V, Liese JG. Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005–2008. BMC Infect Dis. 2011;11:233.
19. Altmann M, Feibig L, Soyka J, von Kries R, Dehnert M, Haas W. Severe cases of pandemic (H1N1)pdm2009 in children, Germany. Emerg Infect Dis. 2011;17:186–92.
20. Altmann M, Feibig L, Buda S, von Kries R, Dehnert M, Haas W. Unchanged severity of influenza A(H1N1)pdm09 infection in children during first postpandemic season. Emerg Infect Dis. 2012;18:1755–62.
21. Bavarian State Office for Statistics and Data Processing. https://www.statistik.bayern.de. Accessed 08 Dec 2015.
22. German Federal Statistical Office. http://www.destatis.de/jetspeed/portal/cms/. Accessed 08 Dec 2015.
23. Joseph C, Togaya Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013;7 Suppl 1:105–13.
24. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson ML, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;CD008965. doi:10.1002/14651858.CD008965.pub4.
25. Muthuri SG, Venketasub S, Myles PR, Leonard-Bee J, Al Khwaikir T, Al Marmun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404.
26. Von Kries R, Weiss S, Falkenhorst G, Wirth S, Kaiser P, Huppertz H-J, et al. Post-pandemic seroprevalence of pandemic influenza A (H1N1)pdm2009 infection (swine flu) among children <18 years in Germany. PLoS ONE. 2011;6:e23895.
27. Launes C, García-García JJ, Martínez-Planas A, Moraga F, Soldevila N, Astigarraga L, et al. Clinical features of influenza disease in admitted children during the first postpandemic season and risk factors for hospitalization: a multicentre Spanish experience. Clin Microbiol Infect. 2013;19:e157–62.
28. Rebolledo J, Igne D, O’Donnell J, Dormegan L, Roland M, Freyne B, et al. Influenza in hospitalized children in Ireland in the pandemic period and the 2010/2011 season: risk factors for paediatric intensive care-unit admission. Epidemiol Infect. 2014;142:1826–35.
29. Green HK, Ellis J, Galiano M, Watson JM, Pepbody RG. Critical care surveillance: insights into the impact of the 2010/11 influenza season relative to the 2009/10 pandemic season in England. Euro Surveill. 2013;18(23).